Potential Breakthroughs in Neurotherapeutics: Alzheimer's Disease, Parkinson's Disease, Depression, Bipolar Disorder, and Schizophrenia

Table of Contents

CHAPTER 1.

INTRODUCTION: NEUROLOGICAL DISORDERS HAVE CLEAR UNMET NEEDS

• 1.1. Clarifying the Problems
• 1.2. Translating the Research

CHAPTER 2.

CURRENT STATUS AND TRENDS IN TECHNOLOGY TRANSFER

• 2.1. The Nature of Technology Transfer Today
• 2.2. Effects of Government Policy on Technology Transfer
  • Dry-eye Therapeutic Agent
  • Blood Glucose Monitoring
• 2.3. Problems Surrounding Technology Transfer
• 2.4. Translational Medicine Comes to Academia

CHAPTER 3.

BACKGROUND INFORMATION ON DISEASES TARGETED FOR THIS REPORT

• 3.1. Alzheimer' s Disease
  • Key Findings Translated into Therapeutic Advances
  • State of the Art in Drug Therapy
• 3.2. Parkinson' s Disease
  • Key Findings Translated into Therapeutic Advances
  • State of the Art in Drug Therapy
• 3.3. Unipolar Depression
  • Key Findings Translated into Therapeutic Advances
  • State of the Art in Commercial Applications
• 3.4. Bipolar Disorder
  • Key Findings Translated into Therapeutic Advances
  • State of the Art in Drug Therapy
• 3.5. Schizophrenia
  • Key Findings Translated into Therapeutic Advances
  • State of the Art in Drug Therapy

CHAPTER 4.

CURRENT BASIC RESEARCH FINDINGS WITH HIGH POTENTIAL FOR COMMERCIAL APPLICATIONS

• 4.1. Alzheimer' s Disease
  • Compounds and Targets Currently in Discovery or Development
  • Disease-Modification Approaches
  • Acetylcholine Receptor Modulation
  • Other Approaches
  • Miscellaneous Mechanisms
  • Recent Advances Potentially Leading to New Therapies
  • p25/Cdk5
  • GSK-3
  • Fyn
  • ERK Pathway
  • Wnt Pathway
  • LR11
  • Amyloid and Ion Channels
  • Aß Degrading Enzymes
  • Oxidative Stress
  • Microtubule-Associated Proteins
  • Prostaglandin E2 E Prostanoid Subtype 2 (PGE2 EP2) Receptors
  • Cholesterol Metabolism and the LDL Receptor
  • Cannabinoid Receptors
• 4.2. Parkinson' s Disease
  • Compounds and Targets Currently in Discovery or Development
  • Recepter Agonists and Antagonists
  • Gene Therapy
  • Other Approaches
  • Recent Advances Potentially Leading to New Therapies
  • Leucine-Rich Repeat Kinase 2 (Lrrk2)
  • Parkin
  • PINK1
  • PPARγ
  • p53
  • Heme Oxygenase-1
  • Nicotinic Acetylcholine Receptors (nAChRs)
  • NADPH Oxidase
• 4.3. Unipolar Depression
  • Compounds and Targets in Discovery or Development
  • Neurotransmitter Modulation
  • Recent Advances Potentially Leading to New Therapies
  • Microtubule Stabilization
  • Cannabinoid CB1 Receptor
  • The Fibroblast Growth Factor (FGF) System
  • p11 (S100A10)
  • PAR-4
  • PSD-95
  • Galanin
• 4.4 Bipolar Disorder
  • Compounds and Targets in Discovery or Development
  • Recent Advances Potentially Leading to New Therapies
  • PSD-95
  • PACAP
  • FAT Gene
  • Protein Kinase C (PKC)
  • BAG-1
  • GSK-3
  • Inositol Metabolism
  • Arachidonic Acid Cascade
• 4.5. Schizophrenia
  • Compounds and Targets in Discovery or Development
  • Serotonin Receptor Antagonists
  • Multiple Factors in Causation
  • Recent Advances Potentially Leading to New Therapies
  • COMT and PRODH
  • Protein Kinase C (PKC)
  • Neuregulin 1
  • DISC1
  • Dysbindin-1
  • PSD-95

CHAPTER 5.

COMMERCIAL POTENTIAL OF SELECTED RESEARCH FINDINGS

• 5.1. Alzheimer' s Disease
  • p25/cdk5
  • Glycogen synthase kinase-3 (GSK-3)
  • Fyn
  • ERK Pathway
  • Wnt Pathway
  • LR11 (SorLA)
  • Amyloid Ion Channels
  • Aß Degrading Enzymes
  • Inflammation and Microglia
  • Oxidative Stress
  • Microtubule-Associated Proteins
  • Prostaglandin E2 E Prostanoid Subtype 2 Receptors (PGE2EP2)
  • Cholesterol Metabolism and the LDL Receptor
  • Cannabinoid Receptors
  • Summary
• 5.2. Parkinson' s Disease
  • Lrrk2
  • Parkin
  • PINK1
  • PPARγ
  • p53
  • Heme Oxygenase-1 (HO-1)
  • Nicotinic Acetylcholine Receptors (nAChRs)
  • NADPH Oxidase
  • Summary
• 5.3. Unipolar Depression
  • Microtubule Stabilization
  • Cannabinoid CB1 Receptor
  • The Fibroblast Growth Factor (FGF) System
  • p11 (S100A10)
  • PAR-4
  • PSD-95
  • Galanin
  • Summary
• 5.4. Bipolar Disorder
  • PSD-95
  • PACAP
  • FAT Gene
  • Protein Kinase C (PKC)
  • BAG-1
  • GSK-3
  • Inositol Metabolism
  • Arachidonic Acid Cascade
  • Summary
• 5.5. Schizophrenia
  • COMT and PRODH
  • Protein Kinase C (PKC)
  • Neuregulin
  • DISC1
  • Dysbindin-1
  • PSD-95
  • Summary

CHAPTER 6.

EXPERT COMMENTARIES

• 6.1. Mark A. Smith, PhD, Professor of Pathology, Case Western Reserve University
• 6.2. Maryka Quik, PhD, Professor, The Parkinson' s Institute
• 6.3. Ross L. Stein, PhD, Director, Laboratory for Drug Discovery in Neurodegeneration, Harvard Center for Neurodegeneration and Repair
• 6.4. Susan L. Stoddard, PhD, Licensing Manager, Mayo Clinic
• 6.5. Michael Palfreyman, PhD, DSc, Vice President, Program Management and Drug Development, En Vivo Pharmaceuticals
• 6.6. C. Anthony Altar, Ph.D., President and CSO, Psychiatric Genomics
• 6.7. Robert G. Urban, PhD, President and CEO, Acretia
• 6.8. Pamela Sklar, MD, PhD, Associate Professor of Psychiatry, Harvard Medical School

CHAPTER 7.

COMPANY PROFILES

• 7.1. Acadia Pharmaceuticals
• 7.2. Axonyx
• 7.3. Biomind
• 7.4. Cortex
• 7.5. Cytos Biotechnology
• 7.6. Elan
• 7.7. En Vivo
• 7.8. ExonHit
• 7.9. GlaxoSmithKline
• 7.10. Lay Line Genomics
• 7.11. Memory Pharmaceuticals
• 7.12. Merck & Co.
• 7.13. Neuro3D
• 7.14. Neurochem
• 7.15. Nymox
• 7.16. Panacea Pharmaceuticals
• 7.17. Psychiatric Genomics
• 7.18. Roche
• 7.19. sanofi-aventis
• 7.20. TorreyPines Therapeutics

References

Index